Clinical Trial

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.
Trial Details
NCT Number NCT06821594
Lead Sponsor Jinnah Postgraduate Medical Centre
Conditions Cutaneous Warts
Enrollment 40 participants
Start Date 2025-04-01
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-12